243 related articles for article (PubMed ID: 10463574)
1. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
[TBL] [Abstract][Full Text] [Related]
2. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
3. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
4. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor.
Kusafuka T; Miao J; Kuroda S; Udatsu Y; Yoneda A
Int J Mol Med; 2002 Oct; 10(4):395-9. PubMed ID: 12239584
[TBL] [Abstract][Full Text] [Related]
5. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules.
Nakatani Y; Masudo K; Miyagi Y; Inayama Y; Kawano N; Tanaka Y; Kato K; Ito T; Kitamura H; Nagashima Y; Yamanaka S; Nakamura N; Sano J; Ogawa N; Ishiwa N; Notohara K; Resl M; Mark EJ
Mod Pathol; 2002 Jun; 15(6):617-24. PubMed ID: 12065775
[TBL] [Abstract][Full Text] [Related]
6. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
[TBL] [Abstract][Full Text] [Related]
7. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
Hollmann CA; Kittrell FS; Medina D; Butel JS
Oncogene; 2001 Nov; 20(52):7645-57. PubMed ID: 11753642
[TBL] [Abstract][Full Text] [Related]
8. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.
Schwartz DR; Wu R; Kardia SL; Levin AM; Huang CC; Shedden KA; Kuick R; Misek DE; Hanash SM; Taylor JM; Reed H; Hendrix N; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2003 Jun; 63(11):2913-22. PubMed ID: 12782598
[TBL] [Abstract][Full Text] [Related]
9. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.
Chen YW; Jeng YM; Yeh SH; Chen PJ
Hepatology; 2002 Oct; 36(4 Pt 1):927-35. PubMed ID: 12297840
[TBL] [Abstract][Full Text] [Related]
10. beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.
Clements WM; Wang J; Sarnaik A; Kim OJ; MacDonald J; Fenoglio-Preiser C; Groden J; Lowy AM
Cancer Res; 2002 Jun; 62(12):3503-6. PubMed ID: 12067995
[TBL] [Abstract][Full Text] [Related]
11. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.
Shiina H; Igawa M; Breault J; Ribeiro-Filho L; Pookot D; Urakami S; Terashima M; Deguchi M; Yamanaka M; Shirai M; Kaneuchi M; Kane CJ; Dahiya R
Clin Cancer Res; 2003 Jun; 9(6):2121-32. PubMed ID: 12796377
[TBL] [Abstract][Full Text] [Related]
12. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
13. Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development.
Zirn B; Wittmann S; Graf N; Gessler M
Cancer Lett; 2005 Mar; 220(1):115-20. PubMed ID: 15737694
[TBL] [Abstract][Full Text] [Related]
14. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
[TBL] [Abstract][Full Text] [Related]
15. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
16. The significance of the Wnt pathway in the pathology of human cancers.
Karim R; Tse G; Putti T; Scolyer R; Lee S
Pathology; 2004 Apr; 36(2):120-8. PubMed ID: 15203747
[TBL] [Abstract][Full Text] [Related]
17. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer.
González-Sancho JM; Aguilera O; García JM; Pendás-Franco N; Peña C; Cal S; García de Herreros A; Bonilla F; Muñoz A
Oncogene; 2005 Feb; 24(6):1098-103. PubMed ID: 15592505
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor.
Fujimori M; Ikeda S; Shimizu Y; Okajima M; Asahara T
Cancer Res; 2001 Sep; 61(18):6656-9. PubMed ID: 11559529
[TBL] [Abstract][Full Text] [Related]
19. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
[TBL] [Abstract][Full Text] [Related]
20. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells.
Chen G; A J; Wang M; Farley S; Lee LY; Lee LC; Sawicki MP
Mol Cancer Res; 2008 Dec; 6(12):1894-907. PubMed ID: 19074834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
